Sánchez E., Sánchez M., López-Cano C., Bermúdez-López M., Valdivielso J.M., Farras-Salles, C, Pamplona R., Torres G., Mauricio D., Castro E., Fernández E., Lecube A.. Is There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project. Nutrients. 2023; 15(1)DOI:10.3390/nu15010203. PMID:36615860. IF:4.800(Q1/2D).

Miñambres I., de Hollanda A., Vilarrasa N., Pellitero S., Rubio M.A., Flores L., Caixàs A., Lobo S., Martinez Salamanca J.I., Acevedo B., Moizé V., Andreu A., Escalada J.. Obesity and fertility. Position statement. Endocrinologia Diabetes y Nutricion. 2023; 70DOI:10.1016/j.endinu.2022.10.002. PMID:. IF:(Q/D).

Pedro-Botet J., Barrios V., Sánchez-Margalet V., Tamargo J., Arrieta F., Gámez J.M., Gimeno-Orna J.A., Escobar C., Gómez-Doblas J.J., Pérez A.. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología. Endocrinologia Diabetes y Nutricion. 2023; 70DOI:10.1016/j.endinu.2022.03.004. PMID:. IF:(Q/D).

Mathiesen E.R., Alibegovic A.C., Corcoy R., Dunne F., Feig D.S., Hod M., Jia T., Kalyanam B., Kar S., Kautzky-Willer A., Marchesini C., Rea R.D., Damm P.. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial. Lancet Diabetes & Endocrinology. 2023; 11(2)DOI:10.1016/S2213-8587(22)00307-2. PMID:36623517. IF:44.000(Q1/1D).